T1	Participants 422 453	Thirty-four eyes of 32 patients
T2	Participants 1341 1348	16 eyes
T3	Participants 1456 1462	2 eyes
T4	Participants 1508 1516	Two eyes
T5	Participants 1558 1565	11 eyes
T6	Participants 1669 1679	PDT group,
T7	Participants 1762 1779	ranibizumab group
T8	Participants 1928 1937	PDT group
T9	Participants 1953 1970	ranibizumab group
T10	Participants 2134 2155	low-fluence PDT group
